Monalizumab is a first-in-class immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab can be used in the study of head and neck squamous cell carcinoma (HNSCC).
Purity:
>99%
CAS Number:
[1228763-95-8]
Target:
Checkpoint
* VAT and and shipping costs not included. Errors and price changes excepted